Seeking Alpha
 

Amgen Inc. (AMGN)

- NASDAQ
  • Nov. 7, 2011, 9:21 AM
    Amgen (AMGN) gains 5.1% on news that the biotech giant will repurchase $5B in shares via a Dutch tender offer at a price between $54 and $60.
    | Comment!
  • Oct. 24, 2011, 4:09 PM
    Amgen (AMGN): Q3 EPS of $1.40 beats by $0.11. Revenue of $3.94B (+3% Y/Y) beats by $70M. Shares +1.6% AH. (PR)
    | Comment!
  • Oct. 24, 2011, 12:10 AM
    Notable earnings after Monday's close: ALB, AMGN, CIM, FTNT, HLX, HMA, HXL, MAS, NFLX, PCL, STM, TXN, VECO, ZION
    | Comment!
  • Oct. 20, 2011, 2:13 PM
    America's most overpaid big-company CEOs based on stock market performance, according to 24/7 Wall Street: John Chambers (CSCO), Tom Ward (SD), Laurence Fink (BLK), Miles White (ABT), William Swanson (RTN), Robert Stevens (LMT), William Weldon (JNJ), Kevin Sharer (AMGN).
    | 3 Comments
  • Oct. 19, 2011, 5:02 PM
    Amgen (AMGN) says it will cut around 380 jobs to restructure its R&D organization, in what the company calls a much-needed shift in resources to late-stage development drugs. The company has a total work force of around 17,600.
    | Comment!
  • Oct. 19, 2011, 11:38 AM
    Some of the world's biggest and best-known stocks have lain comatose for years, many of them leaders in a host of industries - WMT, CSCO, PFE, INTC, GE, MSFT, AMGN, F, TWX, MDT - and among the most widely held stocks in America. More than $2T is locked up in blue chips that have gone absolutely nowhere or down for a decade.
    | 4 Comments
  • Oct. 10, 2011, 6:39 PM
    Maxygen (MAXY) gains in the post-session after it says the U.S. Patent and Trademark Office has rejected all of Amgen's (AMGN) patent claims to certain molecules that potentially cover Maxygen's MAXY-G34 drug candidate. MAXY +3.2% AH.
    | Comment!
  • Sep. 19, 2011, 11:26 AM
    Amgen (AMGN -0.4%) is outperforming a little after the FDA approves the use of its Prolia osteoporosis drug for increasing bone mass in breast cancer and prostate cancer patients. Amgen reported $44M in Prolia sales during Q2, after initially delivering sales that fell short of Street expectations.
    | Comment!
  • Jul. 29, 2011, 8:17 AM
    Amgen (AMGN): Q2 EPS of $1.37 beats by $0.08. Revenue of $3.96B (+4.1% Y/Y) beats by $180M. Sees FY'11 EPS at upper end of $5.00-5.20; Revenue at upper end of $15.1-15.5B. Shares +2.5% premarket. (PR)
    | Comment!
  • Jul. 29, 2011, 12:05 AM
    Notable earnings before Friday's open: ACI, AEP, AGP, AIV, AMGN, AON, AXL, CPN, CVH, CVX, HP, ITT, LPX, MRK, NEM, NWL, PPC, TOT, WY
    | Comment!
  • Jul. 15, 2011, 5:34 PM
    Amgen (AMGN) reaches a settlement with TEVA in its Neupogen patent-infringment lawsuit. The company had filed the claim to block Teva from selling its copycat drug Neutroval, used to prevent infections in patients receiving chemotherapy. Under the agreement, Teva will be prevented from launching Neutroval until 2013. AMGN +1.1%, TEVA -0.1% AH.
    | Comment!
  • Jul. 11, 2011, 9:13 AM
    Micromet (MITI) says it entered into a collaboration agreement with Amgen (AMGN) for the research of BiTE antibodies designed to direct the body's cell-destroying T-cells against tumor cells, representing a new therapeutic approach to cancer therapy. MITI +4.5%, AMGN -0.8% premarket. (PR)
    | Comment!
  • May. 17, 2011, 10:53 AM
    Another favorable trial for Amgen's (AMGN) denosumab drug, used in men to treat prostate cancer, as it's seen to delay bone pain in patients. A fall study showed surprisingly good results; analysts expect the drug's annual sales to reach $2.5B by 2015.
    | Comment!
  • Apr. 20, 2011, 4:09 PM
    Amgen (AMGN): Q1 EPS of $1.34 beats by $0.05. Revenue of $3.7B in-line. Shares +0.6% AH. (PR)
    | Comment!
  • Apr. 20, 2011, 12:10 AM
    Notable earnings after Wednesday's close: AAPL, AMGN, AMR, AXP, BSX, CAKE, CMG, CVA, ESV, ETFC, FFIV, GILD, KNX, LRCX, MAR, NE, NFX, PBCT, QCOM, RRR, SLM, TEX, WDC, WLT, YUM
    | Comment!
  • Mar. 24, 2011, 2:25 PM
    Amgen (AMGN +1%) may introduce its first dividend at an April 21 investor meeting, Bloomberg says, boosting a stock whose value has been chopped by a third since 2006. Unlike other biotechs, Amgen can afford to return money to shareholders because it generates a lot of cash compared with capital expenditures. But the projected 2.3% yield would rank well behind drugmakers PFE, MRK and JNJ.
    | 1 Comment
Visit Seeking Alpha's
AMGN vs. ETF Alternatives
Company Description
Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers human therapeutics. It operates in one business segment being human therapeutics.
Sector: Healthcare
Industry: Biotechnology
Country: United States